Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label single-arm study of SM-1 in advanced small bowel adenocarcinoma
CTR20222242Phase 2Active
- Sponsor
- Shenzhen Zhenxing Pharmaceutical Technology
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SM-1 in small bowel adenocarcinoma (SBA), sponsored by Shenzhen Zhenxing Pharmaceutical Technology. Started Jan 2023; status: active.
02
Drugs
SM-1
03
Conditions
small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on CTR20222242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222242.